The aforementioned trial of a CCL21 gene-modified MoDC in situ vaccination was shown to induce TAA-specific T cell responses in a subset of patients with NSCLC, demonstrating the ability of DCs to promote these responses even in the absence of peptide pulsing [179]. This evidence concerns the gene CCL21 and non-small cell lung carcinoma.